Timothée Olivier, Medical Oncologist and Attending Physician at the Oncology Division of Geneva University Hospital in Switzerland, shared a post on X about a paper by Fabio Conforti et al. published in the Journal of Clinical Oncology:
“Nice to see sensitivity analyses run on digitized curves. Fabio Conforti et al., in their Journal of Clinical Oncology article, seem to disagree with our conclusion after running a sensitivity analysis on the updated results of NATALEE (3-year adjuvant ribociclib in HER2-, HR+ breast cancer).
However, they did not account for the possibility that different reasons for censoring could have affected the two treatment arms differently, which was the core of our analysis.
Check out my new ‘Let’s get ready for ESMO 2025!’ post to get an updated ‘Breaking-ICE’ analysis and more insights about both MonarchE and NATALEE expected ESMO25 updates.”
Title: Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence
Authors: Fabio Conforti, Federico Merlo, Laura Pala, Jacopo Canzian, Benedetta Tinterri, Tommaso De Pas, Marzia Locatelli, James C. Dickerson, Javier Cortes, Dennis J. Slamon, Richard Gelber, and Vincenzo Bagnardi
You can read the Full Article in the Journal of Clinical Oncology.
More posts featuring Timothée Olivier.